FIRST Trial Reaches Target Enrollment
The FIRST trial has reached its target enrollment of 220 patients across Canada, Finland, and Denmark. The study will continue to collect patient information for the next 24 months
The FIRST trial is a multinational trial evaluating the efficacy of surgical treatment in patients diagnosed with femoroacetabular impingement (FAI). The primary objective of the study is to determine whether the surgical correction of the impingement morphology (arthroscopic osteochondroplasty) provides improved clinical results (decreased pain and improved function) compared to arthroscopic lavage of the hip joint. The rationale for this trial includes: (1) a five-fold growth in popularity during the last 10 years in the surgical management of FAI, (2) global uncertainty in the surgical community regarding efficacy of surgical management of FAI, and (3) a lack of compelling randomized trials evaluating the efficacy and safety of FAI surgery on patient important outcomes.